Abstract
Metabolic disorders encompass a heterogeneous group of conditions that commonly affect the heart and contribute adversely to cardiovascular outcomes. As the heart is a metabolically active organ, inborn errors in metabolism (IEMs) often present with cardiac manifestations such as cardiomyopathy, arrhythmia, and valvular dysfunction. More than 40 IEMs are reported to cause cardiomyopathy, including fatty acid oxidation defects, glycogen, lysosomal and perioxisome storage diseases, mitochondrial cardiomyopathies, organic acidaemias, aminoacidopathies and congenital disorders of glycosylation. Studies suggest that IEM account for only 5% of cardiomyopathies; however, their diagnosis is imperative to enable the effective institution of disease-specific management strategies. This review describes the more common genetic defects that affect metabolic pathways and give rise to heart muscle disease.
Zusammenfassung
Metabolische Störungen üben in der Regel einen negativen Einfluss auf das Herz-Kreislauf-System aus. Dies gilt für angeborene Störungen umso mehr. Sie zeigen sich klinisch als Kardiomyopathien, Rhythmusstörungen oder Herzklappenerkrankungen. Mehr als 40 angeborene Stoffwechselstörungen sind inzwischen bekannt. Zu ihnen gehören Störungen der Fettsäureoxidation, Glykogen-, lysosomale und peroxisomale Speichererkrankungen, mitochondriale Kardiomypathien, Azidämien, Aminoazidopathien sowie Störungen der Glykosylierung. Obgleich die angeborenen metabolischen Störungen nur 5% der Kardiomyopathien ausmachen, ist es unverzichtbar, sie zu erkennen, damit eine krankheitspezifische Behandlung vorgenommen werden kann. Die häufigsten Formen werden in diesem Beitrag beschrieben.
Similar content being viewed by others
References
Cox GF (2007) Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol 24(1):15–25
Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85(3):1093–1129
Bonow R MD, Zipes D, Libby P (2011) Braunwald’s heart disease: a textbook of cardiovascular medicine. Vol. 2, 9. edn. Elsevier
Barth PG et al (2004) X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet 126A(4):349–354 (Part A)
Breunig F, Wanner C (2008) Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J Nephrol 21(1):32–37
Nishino I et al (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406(6798):906–910
Ibdah JA, Yang Z, Bennett MJ (2000) Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 71(1–2):182–189
Saudubray JM et al (1999) Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 22(4):488–502
Olsen RK et al (2007) ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130(Pt 8):2045–2054
Roe CR et al (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110(2):259–269
Bonnefont JP et al (2004) Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25(5–6):495–520
Tein I (2003) Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 26(2–3):147–169
Huss JM, Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115(3):547–555
Koopman WJ, Willems PH, Smeitink JA (2012) Monogenic mitochondrial disorders. N Engl J Med 366(12):1132–1141
Anan R et al (1995) Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 91(4):955–961
Holmgren D et al (2003) Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 24(3):280–288
Scaglia F et al (2004) Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 114(4):925–931
Yeager AM (2002) Allogeneic hematopoietic cell transplantation for inborn metabolic diseases. Ann Hematol 81(Suppl 2):16–19
Rohrbach M, Clarke JT (2007) Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67(18):2697–2716
Winchester B, Vellodi A, Young E (2000) The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 28(2):150–154
Butters TD et al (2003) Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc B-Biol Sci 358(1433):927–945
Fan JQ (2007) Pharmacological chaperone therapy for lysosomal storage disorders—leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins. FEBS J 274(19):4943
Grabowski GA (2008) Treatment perspectives for the lysosomal storage diseases. Expert Opin Emerg Drugs 13(1):197–211
Mohan UR et al (2002) Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 91(7):799–804
Stephan MJ et al (1989) Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy. Am J Dis Child 143(7):782–784
Hirth A, Berg A, Greve G (2007) Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 30(5):820
Soliman OI et al (2007) Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. J Inherit Metab Dis 30(5):750–757
Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6(3):489–506
Braunlin EA, Berry JM, Whitley CB (2006) Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98(3):416–418
Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120(2):405–418
Wraith JE et al (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167(3):267–277
Hishitani T et al (2000) Sudden death in Hunter syndrome caused by complete atrioventricular block. J Pediatr 136(2):268–269
Muenzer J et al (1993) Severe mitral insufficiency in mucopolysaccharidosis type III-B (Sanfilippo syndrome). Pediatr Cardiol 14(2):130–132
Valstar MJ et al (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis
George R et al (2001) Severe valvular and aortic arch calcification in a patient with Gaucher’s disease homozygous for the D409H mutation. Clin Genet 59(5):360–363
Kampmann C et al (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97(4):463–469
Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93(4):528–535
Hughes DA et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153–158
Grunewald S (2007) Congenital disorders of glycosylation: rapidly enlarging group of (neuro)metabolic disorders. Early Hum Dev 83(12):825–830
Lin AE et al (1997) Cardiovascular malformations in Smith-Lemli-Opitz syndrome. Am J Med Genet 68(3):270–278
Kollberg G et al (2007) Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 357(15):1507–1514
Regalado JJ, Rodriguez MM, Ferrer PL (1999) Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency. Pediatr Cardiol 20(4):304–307
Hermans MM et al (2004) Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23(1):47–56
Winchester B et al (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93(3):275–281
Ansong AK et al (2006) Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 8(5):297–301
Kishnani PS et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68(2):99–109
Danon MJ et al (1981) Lysosomal glycogen storage disease with normal acid maltase. Neurology 31(1):51–57
Kooi AJ van der et al (2008) Extension of the clinical spectrum of Danon disease. Neurology 70(16):1358–1359
Shen JJ, Chen YT (2002) Molecular characterization of glycogen storage disease type III. Curr Mol Med 2(2):167–175
Carvalho JS et al (1993) Cardiomyopathy of glycogen storage disease type III. Heart Vessels 8(3):155–159
Moon JC et al (2003) Images in cardiovascular medicine. Myocardial fibrosis in glycogen storage disease type III. Circulation 107(7):e47
Moses SW, Parvari R (2002) The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med 2(2):177–188
Ewert R et al (1999) Glycogenosis type IV as a seldom cause of cardiomyopathy—report about a successful heart transplantation. Z Kardiol 88(10):850–856
Arad M et al (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109(3):357–362
Murphy RT et al (2005) Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 45(6):922–930
Gilbert-Barness E (2004) Review: metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci 34(1):15–34
Simma B, Sperl W, Hammerer I (1990) GM1 gangliosidosis and dilated cardiomyopathy. Klin Padiatr 202(3):183–185
Morrone A et al (2000) beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat 15(4):354–366
Bhattacharya K, Gibson SC, Pathi VL (2005) Mitral valve replacement for mitral stenosis secondary to Hunter’s syndrome. Ann Thorac Surg 80(5):1911–1912
Barshes NR et al (2006) Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review. Pediatr Transplant 10(7):773–781
Cederbaum SD et al (2002) Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol Genet Metab 77(3):195–201
Chalmers RA et al (1997) Mitochondrial carnitine-acylcarnitine translocase deficiency presenting as sudden neonatal death. J Pediatr 131(2):220–225
Pierre G et al (2007) Prospective treatment in carnitine-acylcarnitine translocase deficiency. J Inherit Metab Dis 30(5):815
Guertl B, Noehammer C, Hoefler G (2000) Metabolic cardiomyopathies. Int J Exp Pathol 81(6):349–372
Ratliff NB et al (2002) Cardiac arrest in a young marathon runner. Lancet 360(9332):542
Djouadi F et al (2003) Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 54(4):446–451
Frerman FE, Goodman S (2001) Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxireductase:glutaric aciduria type II. In: Scriver, Beaudet et al (eds) The metabolic and molecular baisi of inherited disease. 8th edn. McGraw-Hill, pp 2357–2365
Van Hove JL et al (2003) D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 361(9367):1433–1435
Conflicts of interest
On behalf of all authors, the corresponding author states that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wicks, E., Elliott, P. Genetics and metabolic cardiomyopathies. Herz 37, 598–611 (2012). https://doi.org/10.1007/s00059-012-3659-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-012-3659-0